CorMedix Inc (NASDAQ:CRMD - Get Free Report) CEO Joseph Todisco acquired 80,000 shares of the business's stock in a transaction dated Friday, November 13th. The stock was acquired at an average cost of $4.89 per share, with a total value of $391,200.00. Following the completion of the transaction, the chief executive officer owned 854,749 shares of the company's stock, valued at approximately $4,179,722.61. The trade was a 10.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
CorMedix Stock Performance
Shares of NASDAQ CRMD opened at $4.82 on Tuesday. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $375.67 million, a P/E ratio of 3.75, a P/E/G ratio of 0.90 and a beta of 1.48. CorMedix Inc has a 12 month low of $4.65 and a 12 month high of $13.02. The stock has a 50 day moving average of $7.11 and a 200-day moving average of $7.55.
CorMedix (NASDAQ:CRMD - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 27.12%. The business had revenue of $54.52 million during the quarter, compared to the consensus estimate of $51.76 million. As a group, equities research analysts predict that CorMedix Inc will post 0.52 EPS for the current year.
Hedge Funds Weigh In On CorMedix
Several institutional investors and hedge funds have recently made changes to their positions in CRMD. Goldman Sachs Group Inc. lifted its holdings in CorMedix by 167.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company's stock worth $9,620,000 after purchasing an additional 782,989 shares during the last quarter. Entropy Technologies LP bought a new stake in CorMedix in the 3rd quarter valued at $332,000. Marshall Wace LLP grew its holdings in CorMedix by 53.4% in the 3rd quarter. Marshall Wace LLP now owns 1,195,422 shares of the company's stock valued at $9,205,000 after buying an additional 415,887 shares in the last quarter. Empowered Funds LLC grew its holdings in CorMedix by 10.3% in the 3rd quarter. Empowered Funds LLC now owns 268,323 shares of the company's stock valued at $2,066,000 after buying an additional 25,091 shares in the last quarter. Finally, Bleakley Financial Group LLC acquired a new position in CorMedix in the 3rd quarter valued at $275,000. Institutional investors and hedge funds own 34.18% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on CRMD shares. Royal Bank Of Canada lifted their price objective on shares of CorMedix from $14.00 to $15.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 10th. UBS Group set a $19.00 price objective on shares of CorMedix in a research report on Tuesday, November 10th. Oppenheimer restated an "outperform" rating and set a $13.00 target price (down from $15.00) on shares of CorMedix in a research note on Friday. Needham & Company LLC raised their target price on shares of CorMedix from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, November 10th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of CorMedix in a report on Tuesday, November 10th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $15.22.
Check Out Our Latest Report on CRMD
About CorMedix
(
Get Free Report)
CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].